Obesity: Difference between revisions

Jump to navigation Jump to search
No change in size ,  7 months ago
no edit summary
No edit summary
No edit summary
Line 30: Line 30:


Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., ... & Okechukwu, K. (2023). Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics, 151(2), e2022060640.  
Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., ... & Okechukwu, K. (2023). Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics, 151(2), e2022060640.  
[https://pubmed.ncbi.nlm.nih.gov/33567185/  STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity]


[https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/patients-taking-popular-medications-for-diabetes-and-weight-loss-should-stop-before-elective-surgery American Society of Anesthesiologists. Patients Taking Popular Medications for Diabetes and Weight Loss Should Stop Before Elective Surgery, ASA Suggests]
[https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/patients-taking-popular-medications-for-diabetes-and-weight-loss-should-stop-before-elective-surgery American Society of Anesthesiologists. Patients Taking Popular Medications for Diabetes and Weight Loss Should Stop Before Elective Surgery, ASA Suggests]
Line 38: Line 36:


[https://www.nejm.org/doi/full/10.1056/NEJMoa2208601 Once-Weekly Semaglutide in Adolescents with Obesity]
[https://www.nejm.org/doi/full/10.1056/NEJMoa2208601 Once-Weekly Semaglutide in Adolescents with Obesity]
[https://pubmed.ncbi.nlm.nih.gov/33567185/  STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity]


[https://pubmed.ncbi.nlm.nih.gov/35441470/ STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension]
[https://pubmed.ncbi.nlm.nih.gov/35441470/ STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension]

Navigation menu